Acerogenin A, a natural compound isolated from Acer nikoense Maxim, stimulates osteoblast differentiation through bone morphogenetic protein action

Biochemical and Biophysical Research Communications

Volumn 406, Issue 2, 2011, Pages 211-217

  Kihara, Tasuku ^a   Ichikawa, Saki ^a   Yonezawa, Takayuki ^b   Lee, Ji Won ^b   Akihisa, Toshihiro ^c   Woo, Je Tae ^b   Michi, Yasuyuki ^a   Amagasa, Teruo ^a   Yamaguchi, Akira ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b CHUBU UNIVERSITY   (Japan)

^c NIHON UNIVERSITY   (Japan)

Author keywords

Acerogenin A; BMP; Natural compound; Noggin; Osteoblast; Runx2

Indexed keywords

ACEROGENIN A; ALKALINE PHOSPHATASE; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; NATURAL PRODUCT; NOGGIN; OSTEOCALCIN; OSTEOGENIC PROTEIN 1; RNA 18S; TRANSCRIPTION FACTOR OSTERIX; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG;

ACER; ACER NIKOENSE MAXIM; ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ISOLATION; GENE EXPRESSION; MOUSE; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ACER; ANIMALS; BONE MORPHOGENETIC PROTEINS; BONE REGENERATION; CARRIER PROTEINS; CELL DIFFERENTIATION; CELL LINE; CORE BINDING FACTOR ALPHA 1 SUBUNIT; DIARYLHEPTANOIDS; MICE; OSTEOBLASTS; OSTEOCALCIN; PHENYL ETHERS; RNA, MESSENGER; TRANSCRIPTION FACTORS;

ACER MAXIMOWICZIANUM; MUS;

EID: 79952445351     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.02.017     Document Type: Article

References (31)

1. Wozney J.M., Rosen V., Celeste A.J., Mitsock L.M., Whitters M.J., Kriz R.W., Hewick R.M., Wang E.A. Novel regulators of bone formation: molecular clones and activities. Science 1988, 242:1528-1534.
2. Yamaguchi A., Komori T., Suda T. Regulation of osteoblast differentiation mediated by bone morphogenetic proteins, hedgehogs, and Cbfa1. Endocr. Rev. 2000, 21:393-411.
3. Lee M.H., Kim Y.J., Kim H.J., Park H.D., Kang A.R., Kyung H.M., Sung J.H., Wozney J.M., Ryoo H.M. BMP-2-induced Runx2 expression is mediated by Dlx5, and TGF-beta 1 opposes the BMP-2-induced osteoblast differentiation by suppression of Dlx5 expression. J. Biol. Chem. 2003, 278:34387-34394.
4. Komori T., Yagi H., Nomura S., Yamaguchi A., Sasaki K., Deguchi K., Shimizu Y., Bronson R.T., Gao Y.-H., Inada M., Sato M., Okamoto R., Kitamura Y., Yoshiki S., Kishimoto T. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 1997, 89:755-764.
5. Otto F., Thornell A.P., Crompton T., Denzel A., Gilmour K.C., Rosewell I.R., Stamp G.W., Beddington R.S., Mundlos S., Olsen B.R., Selby P.B., Owen M.J. Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 1997, 89:765-771.
6. Ducy P., Zhang R., Geoffroy V., Ridall A.L., Karsenty G. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 1997, 89:747-754.
7. Nakashima K., Zhou X., Kunkel G., Zhang Z., Deng J.M., Behringer R.R., De Crombrugghe B. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 2002, 108:17-29.
8. Urist M.R. Bone: formation by autoinduction. Science 1965, 150:893-899.
9. Yamaguchi A., Katagiri T., Ikeda T., Wozney J.M., Rosen V., Wang E.A., Kahn A.J., Suda T., oshiki S. Recombinant human bone morphogenetic protein-2 stimulates osteoblastic maturation and inhibits myogenic differentiation in vitro. J. Cell Biol. 1991, 113:681-687.
10. Katagiri T., Yamaguchi A., Komaki K., Abe E., Takahashi N., Ikeda T., Rosen V., Wozney J.M., Fujisawa-Sehara A., Suda T. Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage. J. Cell Biol. 1994, 127:1755-1766.
11. Yamaguchi A., Ishizuya T., Kintou N., Wada Y., Katagiri T., Wozney J.M., Rosen V., Yoshiki S. Effects of BMP-2, BMP-4 and BMP-6 on osteoblast differentiation of bone marrow-derived stromal cell lines, ST2 and MC3T3-G2/PA6. Biochem. Biophys. Res. Commun. 1996, 220:366-371.
12. Sampath T.K., Maliakal J.C., Hauschka P.V., Jones W.K., Sasak H., Tucker R.F., White K.H., Coughlin J.E., Tucker M.M., Pang R.H.L., Corbett C., Ozkaynak E., Oppermann H., Rueger D.C. Recombinant human osteogenic protein-1 (hOP-1) induces new bone formation in vivo with a specific activity comparable with natural bovine osteogenic protein and stimulates osteoblast proliferation and differentiation in vitro. J. Biol. Chem. 1992, 267:20352-20362.
13. Garrett I.R. Anabolic agents and the bone morphogenetic protein pathway. Curr. Top. Dev. Biol. 2007, 78:127-171.
14. White A.P., Vaccaro A.R., Hall J.A., Whang P.G., Friel B.C., McKee M.D. Clinical applications of BMP-7/OP-1 in fractures, nonunions and spinal fusion. Int. Orthop. 2007, 31:735-741.
15. Awad H.A., Zhang X., Reynolds D.G., Guldberg R.E., O'Keefe R.J., Schwarz E.M. Recent advances in gene delivery for structural bone allografts. Tissue Eng. 2007, 13:1973-1985.
16. Bessa P.C., Casal M., Reis R.L. Bone morphogenetic proteins in tissue engineering: the road from laboratory to clinic, part II (BMP delivery). J. Tissue Eng. Regen. Med. 2008, 2:81-96.
17. Nakagawa K., Imai Y., Ohta Y., Takaoka K. Prostaglandin E2 EP4 agonist (ONO-4819) accelerates BMP-induced osteoblastic differentiation. Bone 2007, 41:543-548.
18. Namikawa T., Terai H., Hoshino M., Kato M., Toyoda H., Yano K., Nakamura H., Takaoka K. Enhancing effects of a prostaglandin EP4 receptor agonist on recombinant human bone morphogenetic protein-2 mediated spine fusion in a rabbit model. Spine 2007, 32:2294-2299.
19. Mundy G., Garrett R., Harris S., Chan J., Chen D., Rossini G., Boyce B., Zhao M., Gutierrez G. Stimulation of bone formation in vitro and in rodents by statins. Science 1999, 286:1946-1949.
20. Luisetto G., Camozzi V. Statins, fracture risk, and bone remodeling. J. Endocrinol. Invest. 2009, 32:32-37.
21. Hojo H., Igawa K., Ohba S., Yano F., Nakajima K., Komiyama Y., Ikeda T., Lichtler A.C., Woo J.T., Yonezawa T., Takato T., Chung U.I. Development of high-throughput screening system for osteogenic drugs using a cell-based sensor. Biochem. Biophys. Res. Commun. 2008, 376:375-379.
22. Nagai M., Kubo M., Fujita M., Inoue T., Matsuo M. Studies on the constituents of Aceraceae Plants. II. Structure of aceroside I, a glucose of a novel cyclic diarylheptanoids from Acer nikoense Maxim. Chem. Pharm. Bull. 1978, 26:2805-2810.
23. Nagai M., Kubo M., Fujita M., Inoue T., Matsuo M. Acerogenin A, a novel cyclic diarylheptanoid. J. Chem. Soc. Chem. Commun. 1976, 338-339.
24. Morikawa T., Tao J., Ueda K., Matsuda H., Yoshikawa M. Medicinal foodstuffs. XXXI. Structures of new aromatic constituents and inhibitors of degranulation in RBL-2H3 cells from Japanese folk medicine, the stem bark of Acer nikoense. Chem. Pharm. Bull. 2003, 51:62-67.
25. Shinoda M., Ohta S., Kumasaka M., Fujita M., Nagai M., Inoue T. Protective effect of the bark of Acer nikoense on hepatic injury induced by carbon. Shoyakugaku Zasshi 1986, 40:177-181.
26. Morikawa T., Tao J., Toguchida I., Matsuda H., Yoshikawa M. Structures of new cyclic diarylheptanoids and inhibitors of nitric oxide production from Japanese folk medicine Acer nikoense. J. Nat. Prod. 2003, 66:86-91.
27. +-glucose cotransporter (SGLT) inhibitors from Acer nikoense. Bioorg. Med. Chem. Lett. 2010, 20:1070-1074.
28. Liu T., Gao Y., Sakamoto K., Minamizato T., Furukawa K., Tsukazaki T., Shibata Y., Bessho K., Komori T., Yamaguchi A. BMP-2 promotes differentiation of osteoblasts and chondroblasts in Runx2-deficient cell lines. J. Cell Physiol. 2007, 211:728-735.
29. Bellows C.G., Aubin J.E., Heersche J.N., Antosz M.E. Mineralized bone nodules formed in vitro from enzymatically released rat calvaria cell populations. Calcif. Tissue Int. 1986, 38:143-154.
30. Rosen V. BMP and BMP inhibitors in bone. Ann. NY Acad. Sci. 2006, 1068:19-25.
31. Baron R., Rawadi G., Roman-Roman S. Wnt signaling: a key regulator of bone mass. Curr. Top. Dev. Biol. 2006, 76:103-127.